PT  - JOURNAL ARTICLE
AU  - Amirhoshang Hoseinpour Dehkordi
AU  - Majid Alizadeh
AU  - Pegah Derakhshan
AU  - Peyman Babazadeh
AU  - Arash Jahandideh
TI  - Understanding Epidemic Data and Statistics: A Case Study of COVID-19
AID  - 10.1101/2020.03.15.20036418
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.15.20036418
4099  - http://medrxiv.org/content/early/2020/04/29/2020.03.15.20036418.short
4100  - http://medrxiv.org/content/early/2020/04/29/2020.03.15.20036418.full
AB  - The 2019-Novel-Coronavirus (COVID-19) has affected 181 countries and out of about 1197405 confirmed cases (By April 5). Understanding the transmission dynamics of the infection in each country which affected on a daily basis and evaluating the effectiveness of control policies is critical for our further actions. To date, the statistics of COVID-19 reported cases show more than 80 percent of infected had a mild case of disease, while around 14 percent of infected experienced a severe one and about 5 percent are categorized as critical disease victims. Today’s report (2020-04-05; daily updates in the prepared website) shows the confirmed cases of COVID-19 in US, Spain, Italy, and Germany are 308850, 126168, 124632 and 96092; respectively. Calculating the total Case Fatality Rate (CFR) of Italy (2020-04-04), about 13.3% of confirmed cases passed away. Compared to South Korea’s rate of 1.8% (7 times lower than Italy) and China’s 4% (69% lower than Italy), the CFR of Italy is too high. There are some effective policies that yield significant changes in the trend of cases. The lockdown policy in China, Italy and Spain (the effect observed after some days), Shutdown of all non-essential companies in Hubei (the effect observed after 5 days), combined policy in South Korea and reducing working hours in Iran.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo finding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe link of All mentioned data and referred papers can be found in the following address. http://iuwa.ir/corona/